Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...
Stockhouse Editorial | December 1, 2020 |

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. Clinical-stage biotechnology...
Streetwise Reports | July 2, 2020 |

Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results'

The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report. In an April 20 research note, Dawson James analyst Jason Kolbert wrote that results from Can...
Streetwise Reports | April 23, 2020 |

5 Ways Tech Startups can Compete with the Industry Leaders

It is a common thing for any established industry to be dominated by several large companies. There are eBay and Amazon for eCommerce, Facebook and Snapchat for social media, Uber and Lyft for transportation, etc. Beating such competitors is a tough challenge every ...
Alexey Chalimov | March 18, 2020 |

The Hottest Tech Sector Of 2020: Interview With Sayan Navaratnam

Uber transformed transportation when it spent a fortune turning ride-sharing into a mainstream mode of transportation. But the 2.0 version of ride-sharing is where the real disruption begins. It fixes everything that's wrong and latches onto a mega-trend the giants shouldn't h...
James Stafford, Oilprice.com | March 4, 2020 |

The 'Virus' Technology That Kills Coronavirus Plus Lots of Other Pathogens

TOMI Environmental Solutions Inc.'s (TOMZ:OTCQB) products kill pathogens—safely and effectively. Not just the coronavirus: Ebola, MERS, C. diff spores, sepsis, norovirus, anthrax, Staphylococcus, MRSA, Legionnaire's and Zika. The kill list also includes food borne illnes...
Streetwise Reports | February 19, 2020 |

The next big thing in Nevada

Key to being a successful junior resource investor is doing your due diligence prior to taking a position in a junior, or for that matter, any publicly traded company. That means going over the financials, fully understanding the business, the sector they’...
Richard (Rick) Mills | February 18, 2020 |

Akazoo Is Trading for a Song (for Now)

The disruptive forces of the Internet, technology, streaming and OTT [over-the-top] services are well known. They have not only created new industries but forced existing entities to change their business models in order to survive. This is particularly true of the media ...
Streetwise Reports | February 7, 2020 |

World's major gold miners target copper porphyries

Something has changed in the gold industry. During high gold-price periods the trend was to produce as much as possible - in many cases, irrespective of higher extraction costs per ounce. In a way you can’t blame them for making hay while the sun shone. The g...
Richard (Rick) Mills | November 8, 2019 |

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Earl...
Streetwise Reports | October 18, 2019 |
1 2